LGDN Stock Chart & Stats
€258.00
-€2.00(-0.77%)
At close: 4:00 PM EDT
€258.00
-€2.00(-0.77%)
Day’s Range― - ―
52-Week Range€111.00 - €280.00
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€5.00B
Enterprise Value€3.64K
Total Cash (Recent Filing)€779.40M
Total Debt (Recent Filing)€451.98M
Price to Earnings (P/E)36.7
Beta0.43
Next Earnings
Aug 06, 2026EPS Estimate
1.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.84
Shares Outstanding20,041,061
10 Day Avg. Volume2
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€299.86Price Target Upside16.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)8.01
Revenue Forecast (FY)€254.15M
Bulls Say, Bears Say
Bulls Say
Royalty Revenue GrowthRapid royalty revenue growth reflects durable, contractually backed cash flows that scale with partner sales. Recurring royalties diversify revenue away from one‑time milestones, support high margins and free cash flow, and underpin the company’s royalty aggregator model over the medium term.
Strong Liquidity & FirepowerNearly $1.0B of available capital gives Ligand structural optionality to close acquisitions, fund royalty buys, and sustain deal cadence. This liquidity supports the stated $150–$250M annual deployment plan, lowers financing risk for strategic growth, and preserves flexibility during partner timing variability.
Scale & Diversification From XOMACompleting the XOMA acquisition materially increases asset breadth and therapeutic diversity, reducing single‑asset concentration. Immediate accretion and a larger royalty base improve revenue predictability and competitive position for Ligand’s aggregation strategy across ophthalmology, oncology, CNS and rare diseases.
Bears Say
Dependence On Partner ExecutionLigand’s model relies on third‑party development, regulatory and commercialization progress, making revenue lumpy and timing‑sensitive. Structural partner risk limits forecast visibility, can cause quarter‑to‑quarter swings in royalties and milestones, and constrains predictability of cash generation.
GAAP Volatility From Fair‑Value MovesMaterial mark‑to‑market swings on equity holdings create persistent GAAP volatility separate from operational cash generation. Such nonoperating noise complicates assessment of underlying profitability, may affect stakeholder confidence, and can mask or exaggerate performance across reporting periods.
Higher Leverage & Financing OverhangA meaningful increase in leverage and recent large convertible financings reduce balance sheet optionality and introduce potential future equity overhang. Higher indebtedness and contingent dilution can limit flexibility for opportunistic deals and raise sensitivity to earnings variability or slower partner payouts.
Ligand Pharma News
LGDN FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was €111.00 and its highest was €280.00 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is €5.00B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on May 07, 2026. The company reported €1.413 earnings per share for the quarter, missing the consensus estimate of €1.575 by -€0.161.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma does not currently pay dividends.
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.71.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 20,041,061 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of €1.413 in its last earnings report, missing expectations of €1.575. Following the earnings report the stock price went up 0.513%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in DE:LGDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€299.86 (16.22% Upside)
€299.86 (16.22% Upside)
Blogger Sentiment
Bullish
DE:LGDN Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €4.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
69.21%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGDN Company Deck
LGDN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was broadly positive: the company reported strong underlying operating momentum (royalty revenue +56% YoY, total revenue +14% YoY, adjusted EPS +23% YoY), meaningful near-term and long-term growth catalysts (Filspari approval and Palvella Phase III success), a transformative announced acquisition (XOMA) expected to be immediately accretive and to materially scale the portfolio, and a strong liquidity position. Key risks discussed include GAAP volatility from equity fair-value movements, lumpy Captisol/contract revenue and timing dependence on partner execution, and remaining uncertainty until the XOMA transaction closes and its tax attributes are fully quantified. Overall, the positives — including multiple high-value clinical and commercial catalysts and a materially enlarged, diversified portfolio — outweigh the highlighted near-term financial and timing uncertainties.View all DE:LGDN earnings summariesLGDN Stock 12 Month Forecast
Average Price Target
€299.86
▲(16.22% Upside)
Technical Analysis
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―